Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

NCT04183114 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT04183114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04183114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
Lead sponsor
PT Bio Farma
Phase
Phase 2/3
Overall status
Completed
Start date
September 3, 2019
Completion date
November 11, 2019
Enrollment
540 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital rubella infection, measles